

as a tertiary amino group, whereby claim 85 does not encompass the compound of Selwood. Claims 18-22, 29, 31, 32, 46 and 75 have been amended to depend from new claim 85, and claims 18, 75, 76, 80 and 81 have been amended to exclude Compound No. 5. In view of such amendments, Selwood does not apply to claim 85 and the other noted claims.

As regards the election of species, Applicants do not deny that some species may be patentably distinct from other species. Nevertheless, they are sufficiently related both structurally and functionally that they should all be examined in the same application.

The claims encompassing the elected compound are claims 20, 22, 29-32, 44, 46, 65, 73, 74, 75, 77-80, 82-84 and new generic claim 85.

The claims encompassing the elected disease species are claims 22, 29-32, 46, 63-66, 73, 74, 77 and 79-83, as well (of course) as the claims which do not mention any treatment and therefore are generic to all treatments, including new claim 85.

Applicants now respectfully await the results of a first examination on the merits.